Patents Assigned to Evolva SA
  • Patent number: 9260406
    Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: February 16, 2016
    Assignee: Evolva SA
    Inventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri
  • Publication number: 20150344920
    Abstract: The present disclosure provides methods for identifying anthocyanins with improved stability, color, or hue using a screening method, and producing anthocyanins with improved stability, color, or hue in, for example, host cells comprising one or more heterologous glycosyltransferase nucleic acid molecules and one or more heterologous acyltransferase nucleic acid molecules.
    Type: Application
    Filed: December 23, 2013
    Publication date: December 3, 2015
    Applicant: Evolva SA
    Inventors: Jorgen Hansen, Patricia Hoyle, Michael Naesby, Joseph M. Sheridan, Jonathan R. Heal
  • Publication number: 20150211036
    Abstract: Microorganisms and processes for the recombinant manufacture of clavine-type alkaloids such as cycloclavine, festuclavine, agroclavine, chanoclavine and chanoclavine aldehyde, as well as polypeptides, polynucleotides and vectors comprising such polynucleotides which can be applied in a method for the manufacture of clavine-type alkaloids are provided.
    Type: Application
    Filed: August 13, 2013
    Publication date: July 30, 2015
    Applicants: BASF SE, Evolva SA
    Inventors: Michael Naesby, Christophe Folly, Curt Aimé Friis Nielsen, Anaelle Hatsch, Markus Schwab, Oskar Zelder, Stefan Haefner, Hartwig Schroeder, Birgit Hoff, Andrea Molt, Klaus Ditrich, Michael Breuer, Holger Hartmann, Karsten Koerber
  • Publication number: 20150158838
    Abstract: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 11, 2015
    Applicant: EVOLVA SA
    Inventors: Peteris Alberts, Alexandra Santana Sorensen
  • Patent number: 8986950
    Abstract: A method of producing a low molecular weight organic compound (e.g. a plant or bacteria secondary metabolite) in increased yields involving use of a microorganism cell, which comprises a gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene capable of glycosylating the produced aglycon.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: March 24, 2015
    Assignee: Evolva SA
    Inventors: Joergen Hansen, Thomas Hvid Andersen, Finn Thyge Okkels
  • Patent number: 8962842
    Abstract: Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: February 24, 2015
    Assignee: Evolva SA
    Inventors: Patrick Roussel, Jutta Heim, Peter Schneider, Christian Bartels, Yaoquan Liu, Glen Dale, Daniel Milligan
  • Patent number: 8952053
    Abstract: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Evolva SA
    Inventors: Peteris Alberts, Alexandra Santana Sorensen
  • Patent number: 8895287
    Abstract: A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: November 25, 2014
    Assignee: Evolva SA
    Inventors: Michael Katz, Hans Peter Smits, Jochen Förster, Jens Bredal Nielsen
  • Publication number: 20140288110
    Abstract: 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 25, 2014
    Applicant: EVOLVA SA
    Inventors: Karsten KRISTIANSEN, Prathama S. MAINKAR, Jean-Philippe MEYER, Alexandra Santana SORENSEN
  • Publication number: 20140248668
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a zeaxanthin cleavage dioxygenase alone or in combination with recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce compounds from saffron such as crocetin, crocetin dialdehyde, crocin, or picrocrocin.
    Type: Application
    Filed: August 7, 2012
    Publication date: September 4, 2014
    Applicant: EVOLVA SA
    Inventors: Shriram Raghavan, Jorgen Hansen, Shailendra Sonkar, Sathish Kumar, Murali Panchapagesa, Esben Halkjaer Hansen, Klavs Riishede Hansen, Kalyan Kumar
  • Publication number: 20140245496
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: August 7, 2012
    Publication date: August 28, 2014
    Applicants: EVOLVA SA, INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton
  • Publication number: 20140206051
    Abstract: A method for the production of a stilbenoid, such as resveratrol or pinosylvin, by fermenting plant material such a grape must using a yeast having a metabolic pathway producing said stilbenoid, separating a solids waste material from said fermentation and extracting said stilbenoid.
    Type: Application
    Filed: October 15, 2013
    Publication date: July 24, 2014
    Applicant: Evolva SA
    Inventors: Bo STENHUUS, Hans Peter SMITS, Thomas DURHUUS, Michael KATZ
  • Publication number: 20130344571
    Abstract: A cis- or trans-stilbenoid of the general formula (1): in which each of R1, R2, R3, R4 and R5 is hydrogen or hydroxy, or a glycosylated or oligomeric form thereof, is produced by cultivating a micro-organism producing said stilbenoid, in a multi-phase system comprising at least an aqueous first phase containing said micro-organism and a second phase immiscible with said aqueous phase in which (e.g. as which) said stilbenoid accumulates. The second phase may be said stilbenoid or a free or encapsulated solvent compatible with the growth of the micro-organism, for instance an ester.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 26, 2013
    Applicant: Evolva SA
    Inventors: SCHMIDT Peter Hans, KATZ Michael, STENHUUS Bo, FORSTER Jochen
  • Patent number: 8569024
    Abstract: A method for the production of a stilbenoid, such as resveratrol or pinosylvin, by fermenting plant material such a grape must using a yeast having a metabolic pathway producing said stilbenoid, separating a solids waste material from said fermentation and extracting said stilbenoid.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: October 29, 2013
    Assignee: Evolva SA
    Inventors: Bo Stenhuus, Hans Peter Smits, Thomas Durhuus, Michael Katz
  • Publication number: 20130267561
    Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
    Type: Application
    Filed: March 7, 2013
    Publication date: October 10, 2013
    Applicant: Evolva Sa
    Inventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Mainkar S. Prathama, Melya Hughes Crameri, Thierry Bonnaud, Joanne Kelleher, David Pearson
  • Publication number: 20130253045
    Abstract: The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 26, 2013
    Applicant: Evolva Sa
    Inventors: Peteris Alberts, Alexandra Santana Sorensen
  • Publication number: 20130252882
    Abstract: This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.
    Type: Application
    Filed: January 31, 2012
    Publication date: September 26, 2013
    Applicant: EVOLVA SA
    Inventors: Jutta Heim, Peter Schneider, Patrick Roussel, Daniel Milligan, Christian Bartels, Glenn Dale
  • Publication number: 20130245035
    Abstract: Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof.
    Type: Application
    Filed: September 16, 2011
    Publication date: September 19, 2013
    Applicant: EVOLVA SA
    Inventors: Patrick Roussel, Jutta Heim, Peter Schneider, Christian Bartels, Yaoquan Liu, Glen Dale, Daniel Milligan
  • Patent number: 8536196
    Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: September 17, 2013
    Assignee: Evolva SA
    Inventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri, Thierry Bonnaud, Joanne Kelleher, David Pearson
  • Patent number: 8518677
    Abstract: A cis- or trans-stilbenoid of the general formula (1): in which each of R1, R2, R3, R4 and R5 is hydrogen or hydroxy, or a glycosylated or oligomeric form thereof, is produced by cultivating a micro-organism producing said stilbenoid, in a multi-phase system comprising at least an aqueous first phase containing said micro-organism and a second phase immiscible with said aqueous phase in which (e.g. as which) said stilbenoid accumulates. The second phase may be said stilbenoid or a free or encapsulated solvent compatible with the growth of the micro-organism, for instance an ester.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: August 27, 2013
    Assignee: Evolva Sa
    Inventors: Hans Peter Schmidt, Michael Katz, Bo Stenhuus, Jochen Förster